News Focus

June 10, 2010

Contact: Ms Nadjet Amraoui

Rockland Technimed Ltd and Fresenius-Kabi Product Partnering, , Austria have executed a  partnership agreement today  for manufacturing development of  Oxy-17®  as a ready to use injectable,  imaging media, for invivo, realtime metabolic imaging using an unaltered MRI scanner.

 Fresenius-Kabi  will be RTL's manufacturing  partner for worldwide supply of Oxy-17®  in the required packaging, to RTLs distribution and marketing partners in various markets.

For any information please contact us at

Tel: +1-845-426-3406 , Fax +1-845-436-1109

Email: staff@technimed.com

Regulatory News Focus:

US Food and Drug Administration, Dec 22, 2006:Public Health Advisory

Update on Magnetic Resonance Imaging (MRI) Contrast Agents Containing Gadolinium and Nephrogenic Fibrosing Dermopathy.

Link to US FDA Public Advisory

Health Canada Advises Canadians of Safety Issues Related to Gadolinium-Containing Contrast Agents Used in Magnetic Resonance Imaging (MRI)

Link to Canada Health Advisory

UK.MHRA-Medicines and Healthcare products Regulatory Agency -
Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents

Public Assessment Report

Questions and Answers

Related links:

Internal Medicine News Vol 4 No 2

Nature Clinical Practice Nephrology Vol 3 No 2

 



What the press says :

Rockland Technimed Ltd.
Maratha House, 3 Larissa Court, Airmont, NY USA
Telephone: 001-(845)-426-3406, Fax -001- (845)-426-1109
Email - info@technimed.com Webmaster - webmaster@technimed.com
Copyright © 1999-2007 Rockland Technimed Ltd. All rights reserved.

Oxy-17® is a registered Trade Mark of Rockland Technimed Ltd for: Oxygen-based diagnostic agents, preparations and substances for medical purposes, namely, contrast media for medical imaging for use with MRI diagnostic apparatus, and diagnostic scanning agents in the nature of contrast media for use in In-Vivo imaging.